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Glucocorticoids suppress bone
formation via the osteoclast
Hyun-Ju Kim,1 Haibo Zhao,1 Hideki Kitaura,1 Sandip Bhattacharyya,2 Judson A. Brewer,2
Louis J. Muglia,2 F. Patrick Ross,1 and Steven L. Teitelbaum1
1Department

of Pathology and Immunology and 2Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.

The pathogenesis of glucocorticoid-induced (GC-induced) bone loss is unclear. For example, osteoblast apoptosis is enhanced by GCs in vivo, but they stimulate bone formation in vitro. This conundrum suggests that
an intermediary cell transmits a component of the bone-suppressive effects of GCs to osteoblasts in the intact
animal. Bone remodeling is characterized by tethering of the activities of osteoclasts and osteoblasts. Hence,
the osteoclast is a potential modulator of the effect of GCs on osteoblasts. To define the direct impact of
GCs on bone-resorptive cells, we compared the effects of dexamethasone (DEX) on WT osteoclasts with those
derived from mice with disruption of the GC receptor in osteoclast lineage cells (GRoc–/– mice). While the steroid prolonged longevity of osteoclasts, their bone-degrading capacity was suppressed. The inhibitory effect
of DEX on bone resorption reflects failure of osteoclasts to organize their cytoskeleton in response to M-CSF.
DEX specifically arrested M-CSF activation of RhoA, Rac, and Vav3, each of which regulate the osteoclast cytoskeleton. In all circumstances GRoc–/– mice were spared the impact of DEX on osteoclasts and their precursors.
Consistent with osteoclasts modulating the osteoblast-suppressive effect of DEX, GRoc–/– mice are protected
from the steroid’s inhibition of bone formation.
Introduction
Glucocorticoids (GCs) are central to the treatment of inflammatory and immune disorders. These steroids, however, profoundly
impact the skeleton, particularly when administered for prolonged
periods. In fact, high-dose GC therapy is almost universally associated with bone loss, causing one of the most crippling forms of
osteoporosis. Despite the frequency and severity of GC-induced
osteoporosis, its treatment is less than satisfactory, suggesting
that its pathogenesis is incompletely understood.
Net bone mass represents the relative activities of osteoblasts
and osteoclasts, and there is little question that GCs suppress
bone-forming cells, in vivo, via a process involving accelerated
apoptosis (1, 2). In keeping with these in vivo observations, GCs
blunt expression of molecules such as Runx2 and collagen I (3),
which mediate osteoblast differentiation and function, respectively. Similarly, these steroids prompt marrow mesenchymal cells
to express adipocytic genes (4). Surprisingly, however, addition of
GCs to cultures of osteoprogenitor cells actually increases their
capacity to form mineralized bone nodules (5, 6). This paradox
raises the possibility that GC suppression of bone formation in
vivo reflects, at least in part, targeting of the steroid to intermediary cells, which in turn inhibit the osteoblast.
Bone remodeling is an ever-occurring event characterized by
sequential tethering of the activities of osteoclasts and osteoblasts.
In fact, the majority of acquired, systemic diseases of the skeleton
reflect imbalance between osteoclast and osteoblast activity in the
remodeling process. Remodeling units are initiated by the appearance
of osteoclasts that degrade a packet of bone approximately 50 μm
Nonstandard abbreviations used: BMM, bone marrow macrophage; DEX, dexamethasone; GC, glucocorticoid; GR, GC receptor; GRoc–/– mice, mice with GR deleted
in osteoclast lineage cells; GST, glutathione-S-transferase; PTH, parathyroid hormone; RANKL, receptor activator of NF-κB ligand; TRACP5b, tartrate-resistant acid
phosphatase 5b; TRAP, tartrate-resistant acid phosphatase.
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deep. These resorptive cells are replaced, at the same location, by
osteoblast precursors, which synthesize new bone. The osteoporosis attending menopause or GC therapy reflects failure of osteoblasts to fully restore bone previously resorbed in remodeling
sites. This process establishes that osteoclastic bone resorption, in
some manner, promotes osteoblastic bone formation at the same
location. Similarly, pathologically or pharmacologically inhibited
resorption eventuates in arrested osteoblast activity (7, 8).
Bone resorption reflects the sum of osteoclast recruitment and
death and the rate at which the average cell degrades matrix, each
of which is controversial regarding GC therapy, as the drugs are
variously perceived to suppress (9) or enhance (10) generation of
these cells. In particular, there is little evidence that the steroids
impact the resorptive machinery of the mature polykaryon.
Osteoclasts are members of the monocyte/macrophage family
that differentiate under the influence of 2 requisite cytokines,
namely M-CSF and receptor activator of NF-κB ligand (RANKL)
(11). RANKL is a member of the TNF superfamily, physiologically
expressed by osteoblasts and their precursors as a transmembrane
protein that recognizes its receptor, RANK, on osteoclast lineage
cells at various states of differentiation. GCs, which arrest osteoblast differentiation, also stimulate RANKL (12) and M-CSF (13)
expression, which, in conjunction with the steroid’s antiapoptotic
effects on the mature cell (14), would seemingly increase bone-degradative activity. It is therefore curious that there is little evidence
that accelerated bone resorption contributes to the osteoporosis
complicating prolonged GC therapy (15). In fact, the histological appearance of bones of patients so treated indicates that bone
resorption as well as formation is suppressed (1, 16, 17).
On the other hand, the conundrum of GC-inhibited bone resorption, in the face of stimulated RANKL and M-CSF expression and
prolonged osteoclast lifespan, may reflect direct suppression by
the steroid of the cell’s resorptive machinery. We find, in fact,
that while GCs do delay osteoclast apoptosis, they retard the cell’s
capacity to resorb bone, in vitro and in vivo, by disrupting its cyto-
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Figure 1
DEX impacts osteoclast lineage cells in a differentiation- and cytokine-dependent manner. WT and GRoc–/– BMMs were cultured with
M-CSF (50 ng/ml) in the absence (A) or presence (B) of RANKL (30 ng/ml) with various
concentrations of DEX. After 3 days, proliferation was assessed by BrdU incorporation. (C)
WT BMMs were incubated with or without DEX
(100 nM) in the presence of M-CSF alone or
with RANKL, TNF-α (10 ng/m) or IL-1α (10 ng/
ml) for 3 days. Proliferation was evaluated by
BrdU incorporation assay. (D) WT and GRoc–/–
BMMs were cultured with M-CSF and RANKL
for 5 days to generate mature osteoclasts. DEX
(100 nM) or vehicle was added for the entire
5-day culture period or the last 2 days (L2) or
1 day (L1). After 5 days, the relative apoptosis rate was determined by ELISA. *P < 0.01,
**P < 0.001 within each group.

skeleton. These effects are GC receptor (GR) mediated and specifically reflect blockade of M-CSF–stimulated cytoskeletal organization. Most importantly, the arrested resorption induced by GCs
translates to dampened osteoblast activity, as mice in which the
GR has been conditionally deleted in osteoclast lineage cells are
protected from steroid-induced bone loss. Thus, suppression of
the resorptive phase of remodeling contributes to the retarded
bone formation central to GC-induced osteoporosis.
Results
Dexamethasone exerts variable effects during osteoclast differentiation.
To define the effects of GCs on osteoclast precursor proliferation
and survival of the mature resorptive polykaryon, we assessed the
impact of dexamethasone (DEX) on cells derived from WT mice
and those with conditional disruption of the GR in a macrophage-specific manner (GRoc–/– mice) (18). Validating this model,
immunoblot analysis using GR-specific antibody showed that GR
immunoreactivity is undetectable in lysates of GRoc–/– bone marrow macrophages (BMMs) and mature osteoclasts (Supplemental
Figure 1; supplemental material available online with this article;
doi:10.1172/JCI28084DS1).
Turning to the effects of GCs during different phases of osteoclast differentiation, we found that 10 or 100 nM DEX dosedependently inhibits WT BMM proliferation while having no
effect on GRoc–/– cells (Figure 1A). Interestingly, culture of WT
BMMs in M-CSF and RANKL for 3 days, at which time the cells
were committed to the osteoclast phenotype, completely abrogated
the steroid’s antiproliferative effects (Figure 1B). Next, WT BMMs
were incubated with M-CSF alone or with the osteoclastogenic
cytokines RANKL, TNF-α, or IL-1α. Like RANKL, TNF-α, but
not IL-1α, blocks the inhibitory effect of DEX on M-CSF–induced
BMM proliferation (Figure 1C).
Having explored the impact of GCs on osteoclast precursor proliferation, we turned to apoptosis of the mature, nonreplicating
cell. Thus, at selected times, DEX was added to 5-day osteoclasto-

genic cultures consisting of BMMs in M-CSF and RANKL. Specifically, the steroid was present for the entire culture period (5 d) or
added for the last 2 days or the final 24 hours. Assessment after
5 days, at which time naive cultures contained sheets of mature
osteoclasts, established that DEX arrests apoptosis following
exposure to the steroid as early as 1 day (Figure 1D). These results
demonstrate that while DEX blunts BMM proliferation, it does
not affect cells undergoing osteoclast differentiation for as few as
3 days and protects against apoptosis of mature osteoclasts.
DEX alters osteoclast spreading but not differentiation. We next asked
whether GCs impact osteoclast differentiation. To this end, we
assessed the steroid’s effect on expression of 3 osteoclastic genes in
WT and GRoc–/– BMMs exposed to RANKL and M-CSF for 5 days.
Neither tartrate-resistant acid phosphatase (TRAP), MMP-9, nor cathepsin K mRNAs were present in naive BMMs, but each was induced
indistinguishably in WT and GRoc–/– cells as they underwent osteoclastogenesis in the presence or absence of DEX (Figure 2A). Thus,
neither GCs nor the GR regulate osteoclast differentiation. On the
other hand, the steroid had profound effects on osteoclast spreading. DEX, in concentrations as high as 100 nM, did not affect the
appearance of osteoclasts lacking the GR. In contrast, inhibition of
WT osteoclast spreading was profound at 1 nM of the steroid and
universal at 100 nM (Figure 2, B and C). To determine the stage
of osteoclast differentiation at which GCs inhibit spreading, we
added DEX, for various periods, to osteoclastogenic cultures initiated with WT or GRoc–/– BMMs (Figure 3A). Attesting to a direct
effect on the mature osteoclast, exposure to the steroid during the
last day of osteoclast differentiation was necessary and sufficient
to arrest spreading (Figure 3B). Thus, DEX inhibits spreading of
the mature osteoclast and its capacity to resorb mineralized matrix
and does so independently of cell maturation.
DEX specifically inhibits M-CSF–induced actin organization. The morphological impact of DEX on WT osteoclasts, in the face of normal
differentiation, suggests the steroid may alter actin organization.
To determine whether such is the case, we assessed formation of
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Figure 2
DEX-treated BMMs differentiate into osteoclasts but fail to spread. (A) WT and GRoc–/– BMMs were cultured with M-CSF and RANKL with or
without DEX (100 nM). At day 0 and day 5, RNA was extracted, and the expression of osteoclastogenic markers was analyzed by RT-PCR.
GAPDH served as loading control. (B) WT and GRoc–/– BMMs were cultured with M-CSF and RANKL with or without increasing concentrations
of DEX. Five-day osteoclastogenic cultures were stained for TRAP activity. Magnification, ×250. (C) Statistical analysis of the number of WT and
GRoc–/– spread TRAP-positive multinucleated cells/well. *P < 0.001, **P < 0.0001 versus DEX-untreated WT.

the actin ring, a cytoskeletal structure essential for optimal osteoclastic bone resorption (11). To this end, mature osteoclasts were
generated on dentin. Control cells were maintained in M-CSF and
RANKL, while others were exposed to cold PBS for 5 minutes. The
cells were then stained with rhodamine-phalloidin to visualize the
actin cytoskeleton. As seen in Figure 4A, all osteoclasts maintained
consistently in M-CSF and RANKL exhibited characteristic actin
rings, which disappeared following treatment with cold PBS. Furthermore, incubation of the PBS-exposed cells in cytokine-free
medium for 5 hours failed to restore their actin rings.
M-CSF, RANKL, TNF-α, and IL-1α induce actin ring formation
in mature osteoclasts (19, 20). Thus, we asked whether GCs regulate cytoskeletal organization in these cells in a cytokine-specific
manner. WT and GRoc–/– osteoclasts were plated on dentin and
cultured in osteoclast-generating medium for 5 days. After washing with cold PBS to disrupt actin rings, the resorptive polykaryons were incubated for 5 hours with various cytokines, with or
without DEX. Each cytokine, in the absence of DEX, significantly
restored actin ring formation, an event mirrored by GRoc–/– osteoclasts exposed to the steroid (Figure 4, B–F). While DEX did not
alter RANKL-, TNF-α–, or IL-1α–stimulated actin ring formation
in WT osteoclasts (Figure 4, C–F), the steroid blocked M-CSF–
induced actin ring formation by 73% (Figure 4, B and F).
DEX arrests M-CSF–stimulated intracellular signaling. Because GCs
specifically blunt M-CSF–induced cytoskeletal organization in
osteoclasts, we turned to the signal transduction pathway mediating
this event. As seen in Supplemental Figure 2, M-CSF strongly activated ERK1/2 and modestly induced Akt in committed osteoclast
precursors, but DEX failed to impact either signaling molecule.
2154

Cytoskeletal organization in the osteoclast is regulated by the
small GTPases RhoA (21) and Rac (22). We therefore assessed RhoA
activation in M-CSF–treated WT committed preosteoclasts using a
glutathione-S-transferase (GST) pull-down assay. While RhoA activity was enhanced approximately 5-fold within 5 minutes exposure
to the cytokine, DEX completely blocked the induction (Figure 5A).
Similarly, M-CSF rapidly activated Rac 2.5-fold above control, and
this was, again, entirely abrogated by DEX (Figure 5B).
Vav3 is an osteoclast-specific guanidine nucleotide exchange factor that targets Rac. Like RhoA and Rac, Vav3 is essential for osteoclast cytoskeletal organization (23). Consistent with its effect on
Rac, DEX fully arrested the 5-fold increase in Vav3 tyrosine phosphorylation induced by M-CSF (Figure 5C). Hence, in keeping with
its morphological and functional effects, DEX blunts a major cytoskeleton-organizing signaling pathway in osteoclasts. We also find
that DEX-mediated suppression of M-CSF–activated Vav3 required
16 hours’ exposure to the steroid, indicating that the event is likely
to be genomic rather than nongenomic (Supplemental Figure 3).
DEX inhibits osteoclastic bone resorption in vitro and in vivo. To determine the functional implications of GC inhibition of M-CSF–
induced cytoskeletal organization in the mature osteoclast, we
assessed the capacity of steroid-treated cells to resorb mineralized matrix. First, BMMs were cultured on dentin slices in M-CSF
and RANKL, with or without 100 nM DEX, for the entire 5 days
required to maximize the number of mature osteoclasts. As shown
in Figure 6A, DEX markedly decreased resorption lacuna formation by WT but not GRoc–/– cells. Because this result may reflect
diminished osteoclast number due to suppressed BMM proliferation, we turned to cells committed to the osteoclast phenotype
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Figure 3
DEX inhibits spreading in the later stage of osteoclast differentiation.
WT and GRoc–/– BMMs were cultured for 5 days in M-CSF and RANKL
and stained for TRAP activity. The cells were treated with DEX (100 nM)
for the entire 5 days, the first 3 days (F3), the first 4 days, the last 2
days, or the last day. Control cultures were maintained in the absence
of DEX for 5 days. (A) Duration of exposure to Dex in days. (B) Osteoclastogenic cultures stained for TRAP activity. Magnification, ×250.

inhibition occurs in the absence of the GR (Figure 7C). Thus, consistent with disruption of their cytoskeleton, DEX diminishes the
activity of osteoclasts in vitro and in vivo.
DEX-suppressed bone formation is mediated through osteoclasts. To determine whether GC suppression of osteoclast function translates
into arrested bone formation, we administered DEX (10 mg/kg)
or vehicle to WT and GRoc–/– mice daily for 14 days. Two courses
of the fluorescent marker calcein were injected at 6-day intervals
prior to sacrifice, at which time serum was collected.
As expected, DEX suppressed bone formation in WT mice.
Specifically, the mineral apposition rate, a histomorphometric
marker of the functional capacity of the average osteoblast, and
total bone formation rate were reduced approximately two-thirds
relative to control in DEX-treated WT mice (Figure 8, A–C).
Moreover, serum levels of osteocalcin (Figure 8D) and alkaline
phosphatase (Figure 8E), global biomarkers of bone formation,
were similarly decreased in these animals. In contrast, the steroid
did not impact either parameter of bone formation in mice whose
osteoclasts lacked GRs. On the other hand, osteocyte apoptosis was indistinguishable in DEX-treated WT and GRoc–/– mice
(Figure 8F). Thus, DEX mediates its bone-suppressive effects, at
least in part, indirectly via the osteoclast.

whose proliferative capacity was no longer impacted by the steroid
(Figure 6B). To this end, BMMs were maintained on plastic for 2
days in M-CSF and RANKL. They were then lifted and equal numbers cultured on dentin in the presence or absence of DEX for 3
days. Once again, the steroid arrested resorptive pit formation by
WT osteoclasts, while those lacking the GR receptor were spared.
Having established that GCs impair osteoclast function in vitro,
we asked whether the same obtains in vivo. Hence, we treated WT
and GRoc–/– mice with parathyroid hormone1–34 (PTH1–34), which,
consistent with our in vitro observations, increased osteoclast number equally in both genotypes, independent of DEX (Figure 7A).
On the other hand, the in vivo appearance of PTH1–34–induced
osteoclasts exposed to the steroid was strikingly different from
that of control. Whereas naive, PTH1–34–stimulated osteoclasts
were largely juxtaposed to bone, with robust ruffled membrane
formation, those in mice also receiving DEX typically failed to contact bone and did not develop this resorptive organelle (Figure 7B).
Confirming that DEX suppresses stimulated bone resorption, the
GC blunts the capacity of PTH1–34 to enhance serum tartrate-resistant acid phosphatase 5b (TRACP5b) in WT mice while no such

Discussion
In 1990, Udagawa et al. first generated bone fide osteoclasts in
culture by coculturing marrow macrophages and osteoblast precursors (24). The discovery that RANKL, produced by osteoblasts
and their progenitors, is the key osteoclastogenic cytokine established that marrow stromal cells are essential for physiological
osteoclastogenesis (25).
The alternative concept that osteoblast recruitment to sites of
bone remodeling is mediated by the osteoclast is longer-standing yet suffers from a paucity of mechanistic insights (26). Two
general theories of osteoclast regulation of the osteoblast present
themselves. Specifically, the osteoclast itself may be the source of
unidentified, osteoblast-trophic molecules. Buttressing this argument is the fact that certain forms of osteopetrosis, such as c-src
deficiency, are characterized by abundant, albeit dysfunctional,
osteoclasts, yet bone formation is accelerated (27). In other iterations of the disease, such as that due to lack of c-Fos, osteoclastogenesis is arrested and bone formation dampened (28, 29). An
equally compelling argument holds that the osteoclast mobilizes
matrix-residing growth factors, such as TGF-β and IGFs, which,
in turn, target and activate the osteoblast (30). Regardless of
mechanism, the sequential tethering of osteoclastic and osteoblastic activity has important clinical implications. For example,
antiresorptive agents, such as bisphosphonates, are attended by
suppressed bone formation, a phenomenon that may eventuate in
adynamic bone and its structural consequences (31). Similarly, the
bone anabolic properties of PTH are diminished when it is administered with an antiresorptive drug (7, 8).
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Figure 4
DEX inhibits M-CSF–induced actin ring formation. WT and GRoc–/– BMMs were plated on dentin
and cultured with M-CSF (10 ng/ml) and RANKL
(100 ng/ml). (A) After 5 days, WT cells were fixed
before (Con), after washing with cold PBS (washing control [WC]), or after washing and incubation in α-MEM/10% FBS (media control [MC]) for
5 hours. The fixed cells were stained with FITCphalloidin to visualize actin rings. (B–E) After 5 days
WT and GRoc–/– cells were washed with cold PBS
and incubated with or without DEX (100 nM) in the
presence of M-CSF (25 or 100 ng/ml) (B), RANKL
(100 ng/ml) (C), TNF-α (10 ng/ml) (D), or IL-1α
(10 ng/ml) (E). After 5 hours incubation, the fixed
cells were stained with FITC-phalloidin. (F) The
percentage of osteoclasts (OCs) with recovered
actin ring formation with or without DEX and various cytokines. *P < 0.001. Magnification, ×250.

Prolonged GC therapy leads to yet another example of structurally inferior, adynamic bone, indicating that repressed osteoclast
function may contribute to diminished formation. These observations are in keeping with the suggestion of Weinstein that steroidinduced osteoporosis reflects combined inhibition of both the
osteoblast and osteoclast (1) and indicate that, as in other states
of adynamic bone, GC-mediated inhibition of osteoclast function
retards remodeling and, hence, dampens osteogenesis.
The issue as to whether GCs impact osteoclastic bone resorption has been controversial. The capacity of these steroids to
suppress intestinal absorption and renal tubular reabsorption of
calcium is consistent with a scenario of hormonally stimulated
bone degradation (32). On the other hand, PTH levels are probably not increased in most GC-treated patients, and their skeletal response to PTH-suppressing agents, such as vitamin D, is
2156

modest (32). Similarly, GCs attenuate production of sex steroids,
low levels of which, in other circumstances, promote osteoclastic
bone resorption (33). Hormone replacement therapy, however,
does not retard GC-induced bone loss (34). Therefore, if GCs
impact the osteoclast, they are likely to do so directly or within
the context of locally produced osteoclast-regulating factors
such as RANKL or M-CSF.
Our studies of the effects of GCs on various phases of osteoclast
differentiation and function benefited from the availability of
mice conditionally disrupting the GR in the entire BMM/osteoclast lineage, which permitted us to determine whether individual
biological events are specific and GR mediated. These mutant
mice appear indistinguishable from WT for at least 2 months,
indicating that GC-responsive osteoclasts are not required for
normal skeletal development. Probably reflecting the short dura-
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Figure 5
DEX inhibits M-CSF–induced RhoA, Rac, and Vav3 activation. WT BMMs maintained in M-CSF and RANKL for 3 days were exposed to DEX
(100 nM) or vehicle for 16 hours and then stimulated with M-CSF (100 ng/ml). GTP-RhoA and GTP-Rac were isolated by GST pull-down and
immunoblotted with RhoA- (A) or Rac-specific (B) antibodies. (C) Vav3 was immunoprecipitated from the cell lysate and phosphotyrosine (p-Tyr)
content of the immunoprecipitate determined by immunoblot with anti-phosphotyrosine antibody. In all circumstances, the data are expressed
as fold difference in DEX-exposed (+) relative to vehicle-exposed (–) cells.

tion of treatment, histomorphometrically measured bone mass of
WT and GRoc–/– mice, following 14 days of steroid exposure, was
similar (data not shown).
We found that DEX regulates osteoclast precursor proliferation but does so in a differentiation-dependent manner. Thus,
uncommitted BMMs or those stimulated only by M-CSF to
develop into mature non-osteoclastogenic macrophages, underwent divisional arrest in the presence of DEX. IL-1α, which
alone is not osteoclastogenic (35), also failed to prevent DEXsuppressed BMM proliferation. In contrast, when the cells were
maintained in osteoclastogenic medium containing M-CSF
plus RANKL or TNF-α, the steroid no longer dampened proliferation. Thus, commitment to the bone-resorptive phenotype
protects macrophages from the antiproliferative effects of GCs.
Failure of DEX to suppress RANKL-treated osteoclast precursors was mirrored by unaltered activation of ERKs, which mediates replication of the cell.
Weinstein et al. report that GCs prevent apoptosis of the mature
osteoclast (14), which we confirm. The steroid’s antiapoptotic properties are not attended by Akt activation, indicating that an alternative survival pathway is extant. We also note that the antiapoptotic
effect requires only short exposure to the steroid in the latter phase
of osteoclast differentiation. Despite their prolonged longevity,
however, GC-treated osteoclasts have markedly suppressed boneresorptive activity in vitro and in vivo. GCs induce RANKL and
M-CSF expression and blunt synthesis of the osteoclast-inhibitory
molecule osteoprotegerin (12, 13). These observations, taken with
the normal proliferation of DEX-treated BMMs committed to the
osteoclast phenotype, and the drug’s antiapoptotic effect on the
fully differentiated polykaryon, suggest the steroid would accelerate
bone resorption in vivo. We found, however, that while the number
of osteoclasts in PTH-stimulated WT mice treated with DEX mirrors the number in those that have not received the steroid, their

global bone-resorptive activity is suppressed in a GR-mediated
fashion. This paradox of suppressed bone resorption in the face of
unaltered osteoclast number indicates that the stimulatory effects
of GCs on osteoclast survival are obviated by direct inhibition of
the differentiated cell’s capacity to degrade bone.
The osteoclast is characterized by a unique cytoskeleton, which
undergoes continuous reorganization with different phases of
the resorptive cycle (11). We find that DEX, in low nanomolar
concentrations, disarranges the osteoclast cytoskeleton, yielding cells that fail to spread and ineffectively resorb mineralized
matrix. Such features are characteristic of a variety of resorptive
disorders, such as absence of the cytoskeleton-regulating proteins, c-src (13), or the αvβ3 integrin (36). These in vitro GC-

Figure 6
DEX suppresses osteoclastic bone resorption in vitro. (A) WT and
GR oc–/– BMMs were cultured on dentin with RANKL and M-CSF
with or without DEX. After 5 days, resorption pits were stained with
toluidine blue (arrows). (B) WT and GRoc–/– BMMs were cultured on
plastic in the presence of M-CSF and RANKL. After 3 days the cells
were lifted and replated on dentin in M-CSF and RANKL with or without DEX. Three days later, resorption pits were stained with toluidine
blue. Magnification, ×100.
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Figure 7
DEX suppresses PTH-stimulated bone resorption in vivo. WT and GRoc–/– mice were injected daily for 4 days with vehicle (Con) or PTH or PTH
plus DEX (n = 4). Histological sections of calvariae were stained for TRAP activity. (A) Osteoclast number/unit bone volume. (B) TRAP-stained
histological sections of calvariae (arrows indicate osteoclasts with ruffled membranes in resorption lacunae). Magnification, ×250. (C) Serum
TRACP5b levels at sacrifice. *P < 0.01 versus PTH-treated WT.

induced events are reflected in vivo by small, irregular osteoclasts
that fail to attach to or normally degrade bone and lack the cell’s
key resorptive organelle, its ruffled membrane.
Skeletal degradation occurs in an acidified microenvironment
between the osteoclast and the bone surface that is isolated from
the general extracellular space by an actin ring (11). Insufficient
actin ring generation, in a number of circumstances, is accom-

panied by failure of the osteoclast to spread or adequately resorb
bone. We describe what we believe to be a novel and rapid assay for
actin ring formation in osteoclasts under the influence of individual cytokines. Interestingly, DEX did not alter the capacity of
RANKL, TNF-α, or IL-1α to establish actin rings in committed
osteoclast precursors but substantially suppressed that stimulated
by M-CSF. While M-CSF is classically viewed as a survival and pro-

Figure 8
GRoc–/– mice are protected from DEX-suppressed bone formation. WT and GRoc–/– mice were injected with DEX (10 mg/kg) or vehicle daily
for 14 days. Calcein was administered 8 and 2 days prior to sacrifice. (A) Fluorescent micrographs of representative calcein labels. Magnification, ×100. (B) Measured mineral apposition rate. (C) Measured bone formation rate. (D) Serum osteocalcin levels at sacrifice. (E)
Serum alkaline phosphatase (ALP) levels at sacrifice. (F) Percentage of osteocytes in histological sections of bone undergoing apoptosis.
*P < 0.05, **P < 0.005 versus control.
2158
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liferative cytokine for osteoclast precursors, it also exerts cytoskeletal effects via a signaling pathway shared by the αvβ3 integrin
(37). Thus, the spreading defect of αvβ3 integrin–deficient osteoclasts is rescued by high-dose M-CSF.
The osteoclast cytoskeleton is modulated by a series of small
GTPases including RhoA (38) and Rac (23) that transit to their
GTP bond state under the influence of guanine nucleotide
exchange factors (GEFs). RhoA and Rac are activated in the osteoclast by αvβ3 integrin occupancy or M-CSF, both of which induce
the cell-specific GEF isoform Vav3 (23). Inhibition of RhoA activity or genetic deletion of Rac (22) or Vav3 (23) arrests osteoclastic
bone resorption, and we found that DEX prevents M-CSF–mediated induction of the 3 entities. Hence, GCs suppressed bone resorption by disrupting the cytoskeleton of the mature resorptive cell in
an M-CSF/Vav3/RhoA/Rac-dependent manner.
GCs impact cells by genomic and nongenomic mechanisms.
The steroid’s nongenomic effects occur within seconds to minutes and are mediated by the GR or by other means such as G
protein–coupled receptors (39). Because DEX-mediated suppression of Vav3 activation requires 16 hours, a genomic locus of
action is likely. Whether this genomic effect involves direct DNA
binding of the GR or represents GR associating with an intermediary DNA-interacting protein remains to be determined. In
any event, our findings provide what we believe to be a novel
paradigm for the pathogenesis of a common and often devastating form of osteoporosis that to date has remained largely
refractory to therapeutic intervention.
Methods
Mice. The loxp-floxed GR allele has been described previously (18). Mice used
for these studies were progeny of lysMCre+loxPhomo × loxPhomo matings. The
lysM Cre+ knockin was an F1 cross of 129 × C57, as was the loxP allele (40).
To avoid background drift effects of F2 matings, several breeding pairs were
analyzed and Cre– littermates were always used as controls for the Cre+ mice
from the same parents. All mice were 6–10 weeks old and maintained at the
Animal Facility of Washington University School of Medicine. The Animal
Ethics Committee of Washington University approved all experiments.
Serum TRACP5b activity. Serum TRACP5b activity was measured by ELISA
(Immunodiagnostic Systems), after groups of 4 animals were subcutaneously injected with 10 μg PTH (human fragment 1–34; Bachem) diluted in
25 μl of vehicle (1 mM HCl plus 0.1% bovine serum albumin) or PTH plus
DEX (10 mg/kg) once a day for 4 days. Vehicle alone served as control.
Osteoclast cultures. BMMs were prepared from whole bone marrow of
6- to 10-week-old mice as described previously (14) and cultured without or with DEX in the presence of GST-RANKL (30 ng/ml) and M-CSF
(50 ng/ml) in α-MEM containing 10% charcoal-stripped FBS. The medium
was exchanged every 2 days. Cells were fixed and stained for TRAP activity
after 5 days. To determine actin ring formation, BMMs were cultured on
dentin with GST-RANKL (100 ng/ml) and M-CSF (10 ng/ml). After 5 days,
some cells were fixed and stained with FITC-phalloidin.
Proliferation. Proliferation was determined using the Cell Proliferation
ELISA system (Amersham Biosciences). After 3 days, Brdu was added to
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osteoporosis. Rev. Endocr. Metab. Disord. 2:65–73.
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each well, and cells were incubated for an additional 4 hours. BrdU incorporation was detected following the manufacturer’s instructions.
Osteoclast apoptosis. Osteoclast apoptosis was assessed by ELISA (Cell
Death Detection ELISA; Roche Diagnostics).
Osteocyte apoptosis. Osteocyte apoptosis was identified in bone sections
by in situ nick-end labeling using the Klenow terminal deoxynucleotidyl
transferase (EMD Biosciences) (2).
RT-PCR.Total RNA (1 μg) extracted from cultured cells was used as a
template for cDNA synthesis. Primers were synthesized on the basis of
the reported mouse cDNA sequence. The following primers were used:
for TRAP, 5′-ACAGCCCCCCACTCCCACCCT-3′ and 3′-TCAGGGTCTGGGTCTCCTTGG-5′; for MMP-9, 5′-CCTGTGTGTTCCCGTTCATCT3′ and 3′-CGCTGGAATGATCTAAGCCCA-5′; for cathepsin K,
5′-GGAAGAAGACTCACCAGAAGC-3′ and 3′-GCTATATAGCCGCCTCCACAG-5′; for GAPDH, 5′-ACTTTGTCAAGCTCATTTCC-3′ and 3′TGCAGCGAACTTTATTGATG-5′. Amplification was conducted for
22–30 cycles, each of 94°C for 1 minute, 58°C for 1 minute, and 72°C for
1 minute. Ten microliters of each reaction mixture was analyzed by 1.5%
agarose gel electrophoresis.
Cell signaling. mAbs obtained from Cell Signaling Technology were used
to detect phosphorylated Akt and ERK by immunoblot assay. To assess
Vav3 activation, cell lysates were immunoprecipitated with polyclonal antibody against Vav3 (Upstate USA Inc.), followed by Western blotting using
anti-phosphotyrosine mAb (4G10; Upstate USA Inc.). Active Rho and Rac
were measured using Rho and Rac1 Activation Kits (Pierce), following the
manufacturer’s protocol.
Serum osteocalcin. Serum osteocalcin levels were measured by ELISA
(Biomedical Technologies Inc.).
Serum alkaline phosphatase. Serum alkaline phosphatase activity was assayed
using QuantiChrom Alkaline Phosphatase Assay Kit (BioAssay Systems).
Mineral apposition rate and bone formation rate. Mice were administered fluorescent calcein dye (20 mg/kg) 8 and 2 days prior to sacrifice. Non-decalcified
histological sections of calvariae were prepared and kinetic parameters determined by fluorescent microscopy using OsteoMeasure (Osteometrics).
Statistics. Data are presented as mean ± SD. Statistical significance was
determined by 2-tailed Student’s t test. P values less than 0.05 were considered statistically significant.
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